Form 4: Precision Biosciences Director Reports Vesting of Stock Units and New Equity Grant

Precision Biosciences Director Melinda Brown has reported changes in her beneficial ownership, including the vesting of 9,826 Restricted Stock Units into common stock and the grant of an additional 21,000 Restricted Stock Units.

Summary

• Melinda Brown, a Director of Precision Biosciences Inc. (DTIL), reported changes in her beneficial ownership of company securities.
• On May 27, 2025, 9,826 Restricted Stock Units (RSUs) vested, converting into an equal number of common shares.
• These 9,826 RSUs were originally granted on June 4, 2024, and vested on the earlier of June 4, 2025, or the day prior to the company's next annual meeting.
• Following this vesting, Melinda Brown's direct beneficial ownership of common stock increased to 18,883 shares.
• On June 3, 2025, Ms. Brown was granted an additional 21,000 Restricted Stock Units.
• These new 21,000 RSUs are scheduled to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to her continued service.
• As of the filing date, Ms. Brown beneficially owns 21,000 derivative securities (RSUs) in addition to her common stock holdings.

Sentiment

Score: 5

Explanation: The filing reports routine equity compensation transactions for a director, including RSU vesting and new RSU grants, which are standard practice and do not indicate a significant positive or negative shift in company outlook or performance.

Positives

• The vesting of 9,826 Restricted Stock Units represents a realization of equity compensation for the director.
• The grant of an additional 21,000 Restricted Stock Units indicates continued equity-based compensation for the director, aligning her interests with long-term shareholder value.

Future Outlook

The 21,000 Restricted Stock Units granted on June 3, 2025, are expected to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, contingent on continued service.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded industries, reflecting standard equity compensation practices for corporate directors. It does not provide specific insights into broader industry trends but confirms ongoing executive compensation structures within the biotechnology sector.

Related Party Transactions

• The grant of Restricted Stock Units to Melinda Brown, a director, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The vesting and grant of RSUs are part of the company's established equity compensation plan, which aligns director incentives with shareholder interests over the long term. These are routine and expected compensation events.

Next Steps

• The vesting of the 21,000 Restricted Stock Units is anticipated to occur on the earlier of June 3, 2026, or the day prior to the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Precision Biosciences, DTIL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Director Ownership, Stock Vesting